Global rat model market is expected to exhibit lucrative growth over the forecast period owing to rising advancements in gene editing tools. Increase in incidence of oncology, neurodegenerative, and immunology disorders is expected to fuel growth in the coming years.
Other factors that are anticipated to boost expansion of this industry include increasing investments by government and research organizations for better facilities in order to develop standard protocols and methodology for experimentation using rat models.
Rats offer several advantages over the other rodent models for pre-clinical analysis and research, thus increasing their preference over the other rodent models. These advantages include quick expansion of embryo-derived cells, ease of physiology monitoring, and better learning capabilities, which aid its usage in cognitive research and behavioral analysis.
Increase in preference of personalized medicine, which requires personalized humanized rat models is also expected to attribute towards growth of this industry. Advancement in bioinformatics that leads into development of tools and software for analysis of data developed after pre-clinical research using rat models is anticipated to boost growth.
However, presence of several alternative animal models such as macaques, marmosets, zebrafish, and C.elegans, which are facing recent advancements for utilization in pre-clinical testing and research are expected to restrain growth. Moreover, ethical laws and stringent regulations for use of animals in research also tend to restrain development of this sector.
Rat model market is segmented on the basis of type, technology, service, application, and care products. On the basis of type, this industry is categorized into knockout, out bred, hybrid, immunodeficient, and conditioned rats.
Technology segment of this sector is further classified as nuclear transferase technology, microinjection, and embryonic stem cells. Owing to rise in stem cell based research, embryonic stem cell technology is expected to account for significant growth over the forecast period.
Service segment of this market comprises cryopreservation, breeding, re-derivation, genetic-testing, and quarantine depending on the service provided by the organizations or companies involved in operations.
Application-wise segmentation of this industry includes oncology, CNS, immunology, and & toxicology. Oncology segment is expected to register lucrative growth throughout the forecast period as a consequence of rising incidences of different types of cancers and demand for development of transgenic prognosis methods.
Geographically, the rat model market is segmented into North America, Europe, Asia Pacific, Latin America, and MEA. North America accounted for the largest share with respect to revenue in 2014. Major factors attributing towards large share of this region include comparatively large number of CROs and companies operating in this region and revised funding plans by NIH for patented research.
Europe accounted for the second largest share of the market with respect to revenue in 2014 due to promotion of research projects by the European Union coupled with government initiatives for the treatment of chronic diseases.
Asia Pacific region is expected to exhibit substantial growth over the forecast period on account of rapidly improving healthcare infrastructure in this region. Furthermore, favorable government reimbursement and stipend policies attribute towards research in this region, thereby impacting industry growth positively. Chinese rat model industry is expected to exhibit lucrative growth owing to factors such as less stringent animal safety regulations in this developing economy, thereby driving growth of rat model industry in this region.
The key companies in rat model market include Charles River Laboratories, Harlan Laboratories, Inc., Taconic Biosciences, Inc., genOway S.A., Janvier Labs, Biobserve GmbH, Transposagen Biopharmaceuticals, Inc., SAGE Labs, Transviragen Inc., Biomedical Research Models, Inc., and Covance Inc.
Companies are involved in adopting strategies such as collaborations with small entities operating in this sector and CROs in order to maintain their share. Moreover, these companies are also engaged in producing models that can be used simultaneously for monitoring different diseases thus driving growth in the coming years. The model developed by one of the key companies operating in this industry for analysis of post-traumatic stress and pharmaceutical development for CNS disease prognosis is an example of such strategy.
Avail customized purchase options to meet your research needs:
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.